株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

造血幹細胞移植:パイプライン製品の分析

Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 251517
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
造血幹細胞移植:パイプライン製品の分析 Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 84 Pages
概要

造血幹細胞移植 (HSCT) とは、骨髄や免疫系が損傷している患者の造血機能を再建するための、自家または同種異系の幹細胞の静脈内 (IV) 移植のことを指します。予見されているリスク要因には、出血や感染症、血栓症、心血管疾患などが含まれます。主な治療法には免疫抑制剤などがあります。

当レポートでは、世界各国での造血幹細胞移植向け治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

造血幹細胞移植の概要

治療薬の開発

  • パイプライン製品の概要

造血幹細胞移植:企業で開発中の治療薬

造血幹細胞移植:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

造血幹細胞移植:企業で開発中の製品

造血幹細胞移植の治療薬開発に従事している企業

  • Actinium Pharmaceuticals, Inc.
  • Athersys, Inc.
  • BioLineRx, Ltd.
  • Cell2B S.A.
  • Celldex Therapeutics, Inc.
  • FibroGen, Inc.
  • Novartis AG
  • P2D Bioscience
  • Polyphor Ltd.
  • TaiGen Biotechnology Co., Ltd.
  • Targazyme, Inc.
  • TikoMed AB

造血幹細胞移植:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

造血幹細胞移植:最近のパイプライン動向

造血幹細胞移植:休止中のプロジェクト

造血幹細胞移植:開発が中止された製品

造血幹細胞移植:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8582IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016, provides an overview of the Hematopoietic Stem Cell Transplantation (Immunology) pipeline landscape.

Hematopoietic stem cell transplantation (HSCT) involves the intravenous (IV) infusion of autologous or allogeneic stem cells to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective. Predisposing risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Treatment includes immunosuppressive drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hematopoietic Stem Cell Transplantation (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hematopoietic Stem Cell Transplantation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 3 and 1 respectively for Hematopoietic Stem Cell Transplantation.

Hematopoietic Stem Cell Transplantation (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hematopoietic Stem Cell Transplantation (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hematopoietic Stem Cell Transplantation (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hematopoietic Stem Cell Transplantation (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hematopoietic Stem Cell Transplantation Overview
  • Therapeutics Development
    • Pipeline Products for Hematopoietic Stem Cell Transplantation - Overview
  • Hematopoietic Stem Cell Transplantation - Therapeutics under Development by Companies
  • Hematopoietic Stem Cell Transplantation - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hematopoietic Stem Cell Transplantation - Products under Development by Companies
  • Hematopoietic Stem Cell Transplantation - Companies Involved in Therapeutics Development
    • Actinium Pharmaceuticals, Inc.
    • Athersys, Inc.
    • Bellicum Pharmaceuticals, Inc.
    • Cell2B S.A.
    • Celldex Therapeutics, Inc.
    • Kiadis Pharma N.V.
    • Novartis AG
    • P2D Bioscience
    • Taiga Biotechnologies, Inc.
    • Targazyme, Inc.
  • Hematopoietic Stem Cell Transplantation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ATIR-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPX-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Casin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CDX-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CordSafe - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSC-835 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Iomab-B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-05285401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TBX-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TXA-127 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TZ-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hematopoietic Stem Cell Transplantation - Dormant Projects
  • Hematopoietic Stem Cell Transplantation - Discontinued Products
  • Hematopoietic Stem Cell Transplantation - Product Development Milestones
    • Featured News & Press Releases
      • Jun 30, 2016: Kiadis Pharma Orphan Drug Designation for ATIR101 further expanded to include treatment in a hematopoietic stem cell transplantation
      • May 18, 2016: Kiadis Pharma presents multiple sets of data at the International Society for Cellular Therapy 2016 Annual Meeting
      • Apr 25, 2016: Actinium to Host Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B
      • Apr 06, 2016: Actinium Announces Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B
      • Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101
      • Mar 30, 2016: Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients
      • Mar 29, 2016: Kiadis Pharma to host a webcast of the full dataset on the primary endpoint of its single-dose Phase II trial with ATIR101
      • Mar 08, 2016: Actinium Pharmaceuticals Announces Filing of Provisional Patent Application Related to Commercial Scale Labeling and Processes for Iomab-B
      • Feb 20, 2016: Celldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest at the 2016 BMT Tandem Meeting
      • Feb 02, 2016: Actinium Pharmaceuticals Announces Participation at Upcoming Annual Meeting of Pre-Eminent Blood and Marrow Transplant Organization
      • Nov 30, 2015: Actinium to Present on Iomab-B at 8th Annual LD Micro Main Event Conference on December 2, 2015
      • Apr 23, 2015: Targazyme Announces FDA Concurrence On Targazyme's Special Protocol Assessment For A Planned Phase 3 Registration Trial For The Treatment Of Patients With Hematologic Malignancie
      • Mar 17, 2015: Targazyme and M.D. Anderson Cancer Center Receive FDA IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft vs Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation
      • Feb 10, 2015: Targazyme Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the Severity of Graft Versus Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation
      • Sep 25, 2014: Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Athersys, Inc., H2 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Cell2B S.A. , H2 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Kiadis Pharma N.V., H2 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Novartis AG, H2 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by P2D Bioscience, H2 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Taiga Biotechnologies, Inc., H2 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Targazyme, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hematopoietic Stem Cell Transplantation - Dormant Projects, H2 2016
  • Hematopoietic Stem Cell Transplantation - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top